



The \$1000 Genome Revolution

Luncheon/Webcast of June 7, 2012 at Aureole Restaurant in New York

Abstract

- Is the genome project finally having an impact on all of us?
- Is new fast and cheap technology finally enabling personalized medicine, and breakthroughs in food and industrial applications?
- What does the future of this life science revolution hold?

The human genome project was an international, publicly funded science research project to decipher the sequence, map the location and identify the function of human genes on all chromosomes. The project started in 1990, mapped the genome of a few humans as well as several other species and cost over US \$4B. The genome project drove innovation in various chemical reagents, instruments, tools and data analytics resulting in breakthroughs in fast, low-cost sequencing that are starting to enable a variety of uses. The 1000 dollar genome is generating a true Life Science revolution with extraordinary implications to health, life and beyond. Join us and gain unique insights on the disruptive opportunities of this revolutionary advance in life science and human health.

Panel

Nancy J. Kelley, Founding Executive Director, New York Genome Center

David Darst, Biotechnology Analyst, Orbimed

David Ferreiro, Executive Director and Sr. Life Science Analyst, Oppenheimer

Biographies



Nancy J. Kelley is the Founding Executive Director of NYGC. She has served at the very highest levels of the business, government, nonprofit and academic sectors for over twenty years. Ms. Kelley was formerly senior vice president, business development and strategic operations for Alexandria Real Estate Equities, an investment trust engaged in properties for the life science industry including the East River Science Park project in Manhattan. As a senior executive with Spaulding & Slye Colliers and Colliers International, the life sciences group, she oversaw major development projects for such clients as the National Institutes of Health, Johns Hopkins University, the Massachusetts Institute of Technology and Boston University/ Boston Medical Center. Ms. Kelley was the principal author/editor of *Alchemy*, a first-of-its-kind global life sciences report, and its follow-on publication *Elements*, which provided business counsel to decision-makers at biotechnology, pharmaceutical and healthcare companies. She was a corporate securities lawyer at the Boston law firm of Hale and Dorr (now Wilmer Hale), focused on start-up companies and investment banks in the biotechnology, medical and healthcare industries, among others. Continues on the next page...

Register now at www.cmeacs.org

cmeglobal@gmail.com • T: (212) 984 9309 • www.cmeacs.org

Co-Sponsor



Sponsors



Event Schedule

Location:

Aureole Restaurant
135 W 42nd Street, NYC
(between 6 Ave/ Broadway)

Event Times: (EDT)

11:15 am - 12:00 noon
Registration and
Networking

12:00 noon - 1:00 pm
Luncheon

1:00 pm - 2:15 pm
Presentation & Webcast

Luncheon Fees (*):

\$90 for Non-members
\$70 for 2012 members
of CM&E, CPPA, or NYBA.
Check for Early-bird
discounts .

Webcast : \$20



The \$1,000 Genome Revolution (continued)

Luncheon/Webcast of June 7, 2012 at Aureole Restaurant in New York

Biographies (continued)

Ms. Kelley also has a broad background in the nonprofit, public and academic sectors. She currently serves or has served on boards for The Jackson Laboratory, Beth Israel Deaconess Medical Center, and the Whitehead Institute. She holds a BA in economics from Yale College, a JD from Harvard Law School, and a MPP from the Harvard Kennedy School.



David M. Darst, joined OrbiMed in 2007 to identify investments in biotechnology and medical device companies. Mr. Darst is a co-founder of several biotechnology companies including Good Start Genetics. He also co-founded an internet health company, and worked as a summer associate with McKinsey & Company, Pfizer, and Millennium Pharmaceuticals. Mr. Darst earned an A.B. degree cum laude from Harvard College and an M.B.A. from Harvard Business School. Mr. Darst serves on the board of Potentia Pharmaceuticals, Inc.



David Ferreiro PhD, is an Executive Director and Senior Analyst covering Life Science Tools & Diagnostics. Prior to Oppenheimer, David worked at JMP Securities with Steve Lichtman on the Medical Devices research team. He began his Wall Street career at Banc of America Securities covering biotechnology. He has also worked at Grey Healthcare Group as a biomedical writer and was a Graduate Research Scientist at Albert Einstein College of Medicine. Dave holds a B.A. in Biology from Middlebury College, and an M.S. and a Ph.D. in Microbiology and Immunology from the Albert Einstein College of Medicine.

Register now at www.cmeacs.org

cmeglobal@gmail.com • T: (212) 984 9309 • www.cmeacs.org

Co-Sponsor



Sponsors



2012 CM&E Board

Chair

George Rodriguez
Argeni LLC

Program Chair

James M. Weatherall
SpecialChem S.A.

Secretary

Rhoda Kriesel
Touchstone Marketing

Treasurer

Fred H. Siemer
Siemer Management

Assistant Treasurer

Karin Bartels
Ipintech LLC

Directors

Charles Brumlik
NanoBiz LLC

Neil Burns
Neil A. Burns LLC

Chris Cerimele
Houlihan Lockey

David J. Deutsch
Vista Marketing

Paul Pospisil
Korn/Ferry International

Rick Templeton
Hilbert, Peers & Young Inc.